Reported frontline studies with triplet regimens in CLL
| Agents . | Study . | Regimen . | Patient population . | PFS . | uMRD rate . | Median follow-up . |
|---|---|---|---|---|---|---|
| Ibrutinib-venetoclax-obinutuzumab | Phase 2 | IVO | Median age: 58 | Median: 88.5 months | Marrow: 56%a | 85.6 months (first 25 TN patients) |
| CLL2-GIVe | IVO | Median age: 62 All patients had altered TP53 | Estimated 3-year: 79.9% | Blood: 78%b | NR | |
| GAIA/CLL1319 | IVO | Mean age: 60.7 Median CIRS score: 2 | Estimated 4-year: 85.5% | Blood: 92.2%c | 50.7 months | |
| A04170228 | IVO | Median age: 74 | Estimated 18-month: 85% | Marrow: 86.7%d | 14 months | |
| Acalabrutinib-venetoclax-obinutuzumab | Phase 229 | AVO | Median age: 63 | At 27.6 months: 100% | Blood: 86%e Marrow: 86% | 27.6 months |
| Zanubrutinib-venetoclax-obinutuzumab | BOVen30 | ZVO | Median age: 62 | One progression event, 2 deaths | Both blood and marrow: 89%f | 25.8 months |
| Agents . | Study . | Regimen . | Patient population . | PFS . | uMRD rate . | Median follow-up . |
|---|---|---|---|---|---|---|
| Ibrutinib-venetoclax-obinutuzumab | Phase 2 | IVO | Median age: 58 | Median: 88.5 months | Marrow: 56%a | 85.6 months (first 25 TN patients) |
| CLL2-GIVe | IVO | Median age: 62 All patients had altered TP53 | Estimated 3-year: 79.9% | Blood: 78%b | NR | |
| GAIA/CLL1319 | IVO | Mean age: 60.7 Median CIRS score: 2 | Estimated 4-year: 85.5% | Blood: 92.2%c | 50.7 months | |
| A04170228 | IVO | Median age: 74 | Estimated 18-month: 85% | Marrow: 86.7%d | 14 months | |
| Acalabrutinib-venetoclax-obinutuzumab | Phase 229 | AVO | Median age: 63 | At 27.6 months: 100% | Blood: 86%e Marrow: 86% | 27.6 months |
| Zanubrutinib-venetoclax-obinutuzumab | BOVen30 | ZVO | Median age: 62 | One progression event, 2 deaths | Both blood and marrow: 89%f | 25.8 months |
aAt end of therapy; bAt cycle 12; cAt month 15; dAt cycle 15; eAt start of cycle 16; fBest uMRD at follow-up.
Regimens: AVO, acalabrutinib, venetoclax, and obinutuzumab; IVO, ibrutinib, venetoclax, and obinutuzumab; ZVO, zanubrutinib, venetoclax, and obinutuzumab. NR, not reported; PFS, progression-free survival; uMRD, undetectable measurable residual disease.
Estimated 4-year: 85.5%.